Delayed Nasdaq  -  05/16 04:00:00 pm EDT
0.7800 USD   +0.79%
05/12TRANSCRIPT : Spectrum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 12, 2022
05/12SPECTRUM PHARMA : Q1 Earnings Snapshot
05/12Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spectrum Pharmaceuticals to Participate in B. Riley Securities 2022 Virtual Oncology Conference

01/20/2022 | 07:01am EDT

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A fireside chat is scheduled for Thursday, January 27, 2022 at 9:30 a.m. ET / 6:30 a.m. PT.

A live webcast of the fireside chat will be available from the Investor Relations section of the company’s website at http://investor.sppirx.com/events-and-presentations with a replay available shortly after the event.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2022 Spectrum Pharmaceuticals, Inc. All Rights Reserved

ę Business Wire 2022
05/12TRANSCRIPT : Spectrum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 12, 2022
05/12SPECTRUM PHARMA : Q1 Earnings Snapshot
05/12Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corp..
05/12Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Mar..
05/11Spectrum Pharmaceuticals Names Nora Brennan CFO
05/11Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
05/11Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer
05/06Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Cor..
05/05SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statem..
05/05Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 7,29 M - -
Net income 2022 -86,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,59x
Yield 2022 -
Capitalization 137 M 137 M -
Capi. / Sales 2022 18,8x
Capi. / Sales 2023 1,22x
Nbr of Employees 164
Free-Float 89,8%
Duration : Period :
Spectrum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPECTRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,78 $
Average target price 5,60 $
Spread / Average Target 618%
EPS Revisions
Managers and Directors
Thomas J. Riga President, CEO, CFO & Director
William L. Ashton Chairman
Francois Lebel Chief Medical Officer & Executive Vice President
Lyndah K. Dreiling Senior Vice President-Clinical Development
Dolatrai M. Vyas Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966